We found borderline evidence of a decrease in ovarian cancer risk associated with the XRCC2 variant rs3218536 using a log-additive model in the original data provided by six OCAC sites (OR=0.89, 95% CI 0.78–1.02, P=0.095) with 2763 cases and 5479 controls. Here, XRCC2 is linked to ovarian cancer.